HomeCompareAPYI vs PLD

APYI vs PLD: Dividend Comparison 2026

APYI yields 1000000.00% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APYI wins by $4.7683925249533696e+36M in total portfolio value
10 years
APYI
APYI
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full APYI calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — APYI vs PLD

📍 APYI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPYIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APYI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APYI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APYI
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, APYI beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APYI + PLD for your $10,000?

APYI: 50%PLD: 50%
100% PLD50/50100% APYI
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

APYI
No analyst data
Altman Z
-3.5
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APYI buys
0
PLD buys
0
No recent congressional trades found for APYI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPYIPLD
Forward yield1000000.00%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$4.7683925249533696e+36M$6.50M
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$5,256,436.18
Total dividends collected$4.7683311610149396e+36M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: APYI vs PLD ($10,000, DRIP)

YearAPYI PortfolioAPYI Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,255$555.24+$100.00MAPYI
2$934,786,450,701$934,679,439,252.34$13,062$1,018.59+$934786.44MAPYI
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,903$1,926.67+$8165787108.56MAPYI
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$20,839$3,823.32+$66665884190957.63MAPYI
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$30,464$8,166.08+$508662171058048128.00MAPYI
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$52,054$19,457.30+$3.62723524842849e+21MAPYI
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$109,886$54,188.93+$2.417368115915061e+25MAPYI
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$304,030$186,451.18+$1.5056740286145463e+29MAPYI
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$1,166,125$840,813.32+$8.764771002818475e+32MAPYI
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$6,504,190$5,256,436.18+$4.7683925249533696e+36MAPYI

APYI vs PLD: Complete Analysis 2026

APYIStock

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.

Full APYI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this APYI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APYI vs SCHDAPYI vs JEPIAPYI vs OAPYI vs KOAPYI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.